Cargando…

Cancer patients’ experiences with immune checkpoint modulators: A qualitative study

BACKGROUND: Minimal qualitative data exist on the experiences of cancer patients treated with immune checkpoint inhibitors or costimulatory antibodies. Understanding the day to day experiences of patients being treated with immune checkpoint modulators, and how these relate to their health‐related q...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ala‐Leppilampi, Kari, Baker, Natalie A., McKillop, Chris, Butler, Marcus O., Siu, Lillian L., Spreafico, Anna, Abdul Razak, Albiruni R., Joshua, Anthony M., Hogg, David, Bedard, Philippe L., Leighl, Natasha, Oza, Amit M., Parsons, Janet A., Hansen, Aaron R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196048/ https://www.ncbi.nlm.nih.gov/pubmed/32119767 http://dx.doi.org/10.1002/cam4.2940

Ejemplares similares

Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index
por: Day, Daphne, et al.
Publicado: (2019)

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
por: Taylor, Kirsty, et al.
Publicado: (2020)

A242 DELAYED STEROID TAPER MAY REDUCE RISK OF RELAPSE IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR ASSOCIATED HEPATOTOXICIT
por: Almousawi, F, et al.
Publicado: (2023)

Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT)
por: Genta, Sofia, et al.
Publicado: (2023)

Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy
por: Cunningham, Morven, et al.
Publicado: (2021)

Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry
por: Music, Milena, et al.
Publicado: (2020)

A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events
por: Janse van Rensburg, Helena J., et al.
Publicado: (2023)

Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis
por: Iafolla, Marco A J, et al.
Publicado: (2020)

Treatment preferences of patients with relapsed and refractory multiple myeloma: a qualitative study
por: Parsons, Janet A., et al.
Publicado: (2019)

Factors That Determine the Experience of Transition to an Inpatient Palliative Care Unit for Patients and Caregivers: A Qualitative Study
por: Whitehead, Katherine, et al.
Publicado: (2022)

A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors
por: Diaz-Padilla, Ivan, et al.
Publicado: (2013)

Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy
por: Spiliopoulou, Pavlina, et al.
Publicado: (2023)

Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy
por: Araujo, Daniel V, et al.
Publicado: (2021)

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)
por: Richter, Suzanne, et al.
Publicado: (2013)

Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?
por: Chau, Nicole G, et al.
Publicado: (2011)

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
por: Oliva, M, et al.
Publicado: (2019)

Clinical outcomes of non‐osteogenic, non‐Ewing soft‐tissue sarcoma of bone––experience of the Toronto Sarcoma Program
por: Veitch, Zachary W., et al.
Publicado: (2020)

Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab
por: Watson, Geoffrey Alan, et al.
Publicado: (2022)

Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction
por: Voon, Pei Jye, et al.
Publicado: (2022)

Additional germline findings from a tumor profiling program
por: Stjepanovic, Neda, et al.
Publicado: (2018)

Increasing operational and scientific efficiency in clinical trials
por: Kelly, Deirdre, et al.
Publicado: (2020)

Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
por: Yin, Xiaoqiang, et al.
Publicado: (2022)

The role of IFN-γ-signalling in response to immune checkpoint blockade therapy
por: Wong, Chun Wai, et al.
Publicado: (2023)

Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators
por: Webster, Kimberly A., et al.
Publicado: (2020)

T-cell response to checkpoint blockade immunotherapies: from fundamental mechanisms to treatment signatures
por: Elliot, Thomas A.E., et al.
Publicado: (2023)

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial
por: Stockley, Tracy L., et al.
Publicado: (2016)

The effect of prior cancer on non‐small cell lung cancer trial eligibility
por: Herman, Michael, et al.
Publicado: (2021)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
por: Shao, Jun, et al.
Publicado: (2020)

Emerging Applications of Metabolomic and Genomic Profiling in Diabetic Clinical Medicine
por: McKillop, Aine M., et al.
Publicado: (2011)

DNA damage and repair dependencies of ionising radiation modalities
por: Melia, Emma, et al.
Publicado: (2023)

The final energy crisis
por: McKillop, Andrew, et al.
Publicado: (2005)

Salt and marine products in the Classic Maya economy from use-wear study of stone tools
por: McKillop, Heather, et al.
Publicado: (2018)

Base excision repair and its implications to cancer therapy
por: Grundy, Gabrielle J., et al.
Publicado: (2020)

Primary cardiac sarcomas: A multi‐national retrospective review
por: Chen, Tom Wei‐Wu, et al.
Publicado: (2018)

Lung cancer in never smokers from the Princess Margaret Cancer Centre
por: Korpanty, Grzegorz J., et al.
Publicado: (2018)

Are Patient and Carer Experiences Mirrored in the Practice Reviews of Self-management Support (Prisms) Provider Taxonomy?
por: Sheridan, Nicolette, et al.
Publicado: (2017)

A real‐world data of Immune checkpoint inhibitors in solid tumors from India
por: Noronha, Vanita, et al.
Publicado: (2021)

Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
por: Corke, Lucy K., et al.
Publicado: (2022)

Identification of abscission checkpoint bodies as structures that regulate ESCRT factors to control abscission timing
por: Strohacker, Lauren K, et al.
Publicado: (2021)

Response to immune checkpoint blockade improved in pre-clinical model of breast cancer after bariatric surgery
por: Sipe, Laura M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_paghm8jnoocoqk7g8humt5a5kr